Daiichi Sankyo Unit Seeks $178M From Novartis As Trial Ends

By Dorothy Atkins (July 21, 2021, 9:27 PM EDT) -- Daiichi Sankyo subsidiary's counsel told a California federal jury during trial closings Wednesday that Novartis owes more than $177.8 million in royalties and fixed payments for infringing its skin cancer treatment patents, while Novartis' attorney argued that the patents are invalid and should never have been issued....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!